Quentin McCubbin - Feb 14, 2022 Form 4 Insider Report for Frequency Therapeutics, Inc. (FREQ)

Role
Chief Manufacturing Officer
Signature
/s/ James P. Abely, Attorney-in-Fact for Quentin McCubbin
Stock symbol
FREQ
Transactions as of
Feb 14, 2022
Transactions value $
-$5,461
Form type
4
Date filed
2/16/2022, 04:04 PM
Previous filing
May 19, 2021
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FREQ Common Stock Options Exercise +17.5K +145.07% 29.6K Feb 14, 2022 Direct F1, F2
transaction FREQ Common Stock Sale -$5.46K -1.26K -4.27% $4.33* 28.3K Feb 15, 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FREQ Restricted Stock Unit Options Exercise -17.5K -50% 17.5K Feb 14, 2022 Common Stock 17.5K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 Includes 2063 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2021.
F3 Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022.